ERASE: Endovascular treatment plus exercise versus exercise alone to treat claudication

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the number of peripheral angioplasties has increased, proving highly effective for this condition. The aim of this study was to compare the clinical effectiveness of endovascular revascularization plus exercise versus exercise alone in patients with intermittent claudication.

The study included 212 patients with intermittent claudication over 3 months and obstructions greater than 50% in aorto/iliac or femoropopliteal territory susceptible of angioplasty. 

The primary endpoint was the maximum walking distance (30 minutes Gardner protocol). At 12 months follow-up the intervention group was successfully treated in 96% of cases (62 % with stent implantation) and received an average of 30 supervised exercise sessions versus 43 sessions for the exercise alone group. In the exercise group that also received angioplasty a significantly greater distance traveled per month, 6 months and 1 year was observed in addition to improving likewise in all secondary endpoints.

Conclusion:

In patients with intermittent claudication, the combination of endovascular therapy plus supervised exercise resulted in functional improvement and quality of life versus supervised exercise only.

Discussion


Farzin Fakhry
2013-11-19

Original title: Randomized Comparison of Endovascular Revascularization Plus Supervised Exercise Therapy Versus Supervised Exercise Therapy Only in Patients With Peripheral Artery Disease and Intermittent Claudication: Results of the Endovascular Revascularization and Supervised Exercise (ERASE) Trial

More articles by this author

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility of dose adjustment by genetics has been...

RADAR AF: High-frequency ablation versus pulmonary vein isolation to treat atrial fibrillation

Atrial fibrillation is initiated by focal triggers and maintained by an atrial substrate called fractioned complex of atrial electrograms. Isolating the pulmonary veins (triggers)...

EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start of therapy. The CYP2C9 gene polymorphism (involved...

ENGAGE AF-TIMI 48: Endoxaban versus warfarin in atrial fibrillation

The endoxaban is an oral direct inhibitor of factor Xa with a rapid onset of action and a half-life of 8-10 hours. Endoxaban efficacy...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...